memo - Magazine of European Medical Oncology

, Volume 11, Issue 4, pp 291–293 | Cite as

ASCO update 2018: upper gastrointestinal cancer

  • Bettina Sonnweber
  • Ewald WöllEmail author
short review


Results from studies in upper gastrointestinal cancer presented at the 2018 American Society of Clinical Oncology (ASCO) meeting are promising. Prophylactic treatment of Barrett’s esophagus with high proton pump inhibitor therapy plus aspirin showed positive results on death, esophageal adenocarcinoma and dysplasia. Current studies on the treatment of gastric cancer included the following: S‑1 plus docetaxel as postoperative adjuvant chemotherapy in Asian patients, triplet therapy (cisplatin, S1, and docetaxel) in Asian patients, paclitaxel vs. pembrolizumab, and a biomarker study for trastuzumab continuation. Advances in the treatment of pancreatic cancer are likely to be practice changing: combined chemotherapy mFOLFIRINOX clearly improved disease-free survival in patients with resected pancreatic ductal adenocarcinomas. In the palliative setting, the introduction of FOLFIRINOX and gemcitabine/nab-paclitaxel may allow treatment with lower toxicity and allow broader patient selection. In the treatment of cholagiocellular cancer, gemcitabine plus S‑1 was non-inferior to gemcitabine plus cisplatin. Preliminary data in the treatment of neoendocrine tumors with temozolomide plus capecitabine are promising. Finally, the second-line treatment of hepatocellular carcinoma with ramucirumab showed a significant survival benefit.


Esophageal cancer Gastric cancer Pancreatic cancer Neuroendocrine tumors Hepatocellular carcinoma 


Conflict of interest

B. Sonnweber and E. Wöll declare that they have no competing interests.


  1. 1.
    Jankowski J, de Caestecker J, Love S, et al. Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial ASPECT trial. J Clin Oncol. 2018; Abstr LBA4008.CrossRefGoogle Scholar
  2. 2.
    Kodera Y, Yoshida K, Kochi M, et al. A randomized phase III study comparing S‑1 plus docetaxel with S‑1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). J Clin Oncol. 2018; Abstr 4007.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yamada Y, Boku N, Mizusawa J, et al. Phase III study comparing triplet chemotherapy with S‑1 and cisplatin plus docetaxel versus doublet chemotherapy with S‑1 and cisplatin for advanced gastric cancer (JCOG1013). J Clin Oncol. 2018; Abstr 4009.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dijksterhuis WPM, van Oijen MGH, Verhoevenet RHA, et al. Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: a real world evidence study. J Clin Oncol. 2018; Abstr 4064.CrossRefGoogle Scholar
  5. 5.
    Fuchs CS, Ozguroglu M, Bang YJ, et al. Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: phase 3 KEYNOTE-061 trial. J Clin Oncol. 2018; Abstr 4062.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sukawa Y, Makiyama A, Esakiet T, et al. Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and paltinum (WJOG7112G). J Clin Oncol. 2018; CrossRefGoogle Scholar
  7. 7.
    Conroy T, Hammel P, Hebbar M, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018; Abstr LBA4001.CrossRefGoogle Scholar
  8. 8.
    Van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; Abstr LBA4002.CrossRefGoogle Scholar
  9. 9.
    Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol. 2018; Abstr 4000.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ueno M, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S‑1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). J Clin Oncol. 2018; Abstr 4014.CrossRefGoogle Scholar
  11. 11.
    Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG_ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(Abstr 4004).CrossRefGoogle Scholar
  12. 12.
    Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind, placebo controled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36(suppl; abstr 4003)Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.St. Vinzenz Hospital ZamsZamsAustria

Personalised recommendations